Status:
UNKNOWN
Immunodeficiency in MS
Lead Sponsor:
Advanced Neurosciences Institute
Collaborating Sponsors:
Novel Pharmaceutics Institute
Conditions:
Multiple Sclerosis
Hypogammaglobulinemia
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to identify if there is a relationship between multiple sclerosis disease-modifying therapy exposure, immunodeficiencies, and infection risk in subjects living with MS.
Detailed Description
The purpose of this study is to identify if there is a relationship between multiple sclerosis disease-modifying therapy exposure, immunodeficiencies, and infection risk in subjects living with MS. By...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- One or more immunoglobulin level results and medical history available
- 18 years of age or older at the time of data collection
- Patients with first symptom MS or other isolated demyelinating syndromes, neuromyelitis optica, or rheumatic-associated CNS inflammation
- Exclusion Criteria:
- No evidence of CNS autoimmune disease
- Less than 18 years of age at the time of data abstraction
- Undergoing plasma exchange at the time of any lab tests drawn
Exclusion
Key Trial Info
Start Date :
June 29 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 30 2021
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT04447937
Start Date
June 29 2020
End Date
July 30 2021
Last Update
June 25 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Advanced Neurosciences Institute
Franklin, Tennessee, United States, 37064